Dataset Information


Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.

ABSTRACT: Based on previous reports, the efficacy of lenvatinib against cancer is mainly attributed to its antiangiogenic activity and its ability to suppress tumor proliferation, which are mediated by targeting receptor tyrosine kinases (RTKs). However, the effects of lenvatinib on tumor immune modulation have rarely been explored. Here, we show that lenvatinib effectively inhibited murine melanoma and renal cancer, and this inhibition was associated with enhanced tumor infiltration by natural killer (NK) cells. Critically, lenvatinib-induced tumor growth inhibition was attenuated by antibody-mediated NK cell depletion or the blockade of NK cell chemotaxis with an anti-CXCR3 blocking antibody. In addition, the expression of natural cytotoxicity receptors (NCRs) by tumor-infiltrating NK cells and the expression of cytotoxic cytokines in the tumor tissue were also augmented by lenvatinib. These data thus suggest that lenvatinib may be used not only as a direct cytotoxic drug against tumor angiogenesis and proliferation but also as a potent adjunct for enhancing the efficacy of immune-based cancer therapies by enhancing the tumor infiltration and activation of NK cells.


PROVIDER: S-EPMC6682710 | BioStudies | 2019-01-01


REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6762047 | BioStudies
2018-01-01 | S-EPMC6272102 | BioStudies
2019-01-01 | S-EPMC6514059 | BioStudies
2019-01-01 | S-EPMC6392299 | BioStudies
1000-01-01 | S-EPMC4399030 | BioStudies
2016-01-01 | S-EPMC5095235 | BioStudies
2017-01-01 | S-EPMC5331066 | BioStudies
2014-01-01 | S-EPMC4156793 | BioStudies
1000-01-01 | S-EPMC2673866 | BioStudies
2019-01-01 | S-EPMC6982268 | BioStudies